Income statement, balance sheet and cash flow statement for the last 3 fiscal years, taken from the XBRL data MiniMed Group, Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2024
FY2026
FY2026
Revenue
2,469
2,715
3,102
Cost of revenue
1,032
1,187
1,422
Gross profit
1,436
1,528
1,680
Research and development
437
436
448
Selling, general and administrative
1,057
1,080
1,183
Operating income
-69
-146
-190
Other non-operating income
-1
-1
1
Pre-tax income
-70
-147
-189
Income tax
38
52
128
Net income to minority interests
5
15
16
Net income
-112
-213
-333
EBITDA
60
-3
-34
EPS, basic
-0.44
-0.84
-1.30
EPS, diluted
-0.44
-0.84
-1.30
Shares, basic (weighted)
253
253
257
Shares, diluted (weighted)
253
253
257
Balance sheet
FY2024
FY2026
FY2026
Cash and equivalents
54
11
298
Receivables
570
200
Inventory
311
341
Other current assets
48
54
Total current assets
939
1,348
Property, plant and equipment
706
711
Lease right-of-use assets
66
52
Goodwill
2,255
2,256
Intangible assets
132
107
Other non-current assets
150
147
Total assets
4,201
4,630
Accounts payable
205
163
Accrued liabilities
182
163
Deferred revenue
11
15
Total current liabilities
710
702
Lease liabilities
56
45
Other non-current liabilities
162
317
Total liabilities
871
1,019
Paid-in capital
0
3,736
Retained earnings
0
-116
Other comprehensive income
3
-12
Shareholders' equity
3,448
3,330
3,611
Minority interests
0
0
Total equity
3,448
3,330
3,611
Total liabilities and equity
4,201
4,630
Shares outstanding
0
0
281
Cash flow statement
FY2024
FY2026
FY2026
Net income
-107
-198
-317
Depreciation and amortization
129
143
156
Stock-based compensation
38
41
46
Deferred income tax
3
-2
-50
Change in inventory
5
-19
-29
Cash from operations
41
140
-197
Capital expenditures
-148
-193
-223
Purchases of investments
-5
0
0
Sales and maturities of investments
11
0
0
Cash from investing
-157
-193
-233
Cash from financing
112
10
716
Net change in cash
-4
-43
287
Free cash flow
-107
-53
-420
Income taxes paid
0
0
2
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to July 31, 2026; growth uses fiscal years. Valuation uses the share price of $19.98 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Return on equity (ROE)
-8.7%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-6.7%
Net income / average total assets.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
14.3%
Revenue vs the same period a year earlier. Only from a positive base.
Gross profit growth, 1y
9.9%
Gross profit vs the same period a year earlier. Only from a positive base.
Operating cash flow growth, 1y
-240.7%
Operating cash flow vs the same period a year earlier. Only from a positive base.
Book value growth, 1y
8.4%
Book value vs the same period a year earlier. Only from a positive base.
Total assets growth, 1y
10.2%
Total assets vs the same period a year earlier. Only from a positive base.
Share count change, 1y
1.5%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
1.81x
Current assets / current liabilities.
Quick ratio
0.49x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
0.26x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Book value per share
$12.87
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/B
1.55x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
4.44x
Market cap / tangible book value, when positive.
Earnings yield
-5.6%
Net income / market cap (the inverse of P/E).
What was MiniMed Group, Inc.'s revenue in fiscal 2026?
MiniMed Group, Inc. reported revenue of $3.10B for fiscal 2026, 14.3% higher than the year before.
Was MiniMed Group, Inc. profitable in fiscal 2026?
No. It reported a net loss of $333.0M.
How much free cash flow did MiniMed Group, Inc. generate in fiscal 2026?
Cash from operations of $197.0M minus capital expenditures of $223.0M left free cash flow of -$420.0M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.